V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Adaptive Biotechnologies Executive Compensation (FY25)

ADPT · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): June 9, 2026
201 figures on this page: 195 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
Chad Robins was paid $9,081,690 in total compensation as Chief Executive Officer and Chairman for fiscal 2025, and compared with the $4,973,301 reported for fiscal 2024, Robins' total was 82.6% higher. The company reported a chief executive pay ratio of 47:1 for fiscal 2025, against median employee compensation of $194,620. The say-on-pay proposal drew 96.7% of votes cast for or against in favor at the meeting held June 5, 2026 for fiscal 2025. Companies named in the disclosed peer group include Allogene Therapeutics, Inc., bluebird bio, Inc., CareDx, Inc., Castle Biosciences, Inc. and Codexis, Inc., among others.
Chief executive, fiscal 2025
◇
Chad Robins
Latest say-on-pay support
=
June 5, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Chad Robins: $4,973,301 → $9,081,690 (82.6% higher)
Say-on-pay support: 98.8% → 96.7% (2.1 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Adaptive Biotechnologies' chief executive and what were they paid?
Chad Robins was paid $9,081,690 in total compensation as Chief Executive Officer and Chairman for fiscal 2025. Compared with the $4,973,301 reported for fiscal 2024, Robins' total was 82.6% higher.
What was Adaptive Biotechnologies' say-on-pay result?
The say-on-pay proposal drew 96.7% of votes cast for or against in favor at the meeting held June 5, 2026 for fiscal 2025.
Which companies are in Adaptive Biotechnologies' peer group?
Companies named in the disclosed peer group include Allogene Therapeutics, Inc., bluebird bio, Inc., CareDx, Inc., Castle Biosciences, Inc. and Codexis, Inc., among others.
What is Adaptive Biotechnologies' chief executive pay ratio?
The company reported a chief executive pay ratio of 47:1 for fiscal 2025, against median employee compensation of $194,620.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chad Robins
Chief Executive Officer
◇—◇—◇—◇◇
Kyle Piskel
President and Chief Operating Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chad Robins
Chief Executive Officer
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chad Robins
Chief Executive Officer
◇—◇—◇—◇◇
Kyle Piskel
President and Chief Operating Officer
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chad Robins
Chief Executive Officer and Chairman
◇—◇—◇—◇◇
Harlan Robins
Chief Scientific Officer
◇—◇—◇—◇◇
Julie Rubinstein
President and Chief Operating Officer
◇—◇—◇—◇◇
Susan Bobulsky
Chief Commercial Officer, MRD
◇—◇◇◇—◇◇
Kyle Piskel
Chief Financial Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Chad RobinsPSU◇——◇——◇
Chad RobinsRSU◇——◇——◇
Harlan RobinsRSU◇——◇——◇
Harlan RobinsPSU◇——◇——◇
Julie RubinsteinRSU◇——◇——◇
Julie RubinsteinPSU◇——◇——◇
Kyle PiskelRSU◇——◇——◇
Kyle PiskelPSU◇——◇——◇
Susan BobulskyPSU◇——◇——◇
Susan BobulskyRSU◇——◇——◇
Susan BobulskyOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Kyle PiskelRSU◇◇——
Option◇—◇3/4/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Susan BobulskyRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/4/2032
Option◇—◇3/4/2034
Option◇—◇3/4/2035
Option◇—◇3/6/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/4/2032
RSU◇◇——
RSU◇◇——
Chad RobinsRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Julie RubinsteinOption◇—◇3/6/2033
RSU◇◇——
Option◇—◇3/4/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Peter Neupert
Lead independent director
◇◇◇———◇
Michelle Griffin
◇◇◇———◇
Robert Hershberg
◇◇◇———◇
Katey Owen
◇◇◇———◇
Michael Pellini
◇◇◇———◇
Chad Robins served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Allogene Therapeutics, Inc. ALLO
  • bluebird bio, Inc. BLUE
  • CareDx, Inc. CDNA
  • Castle Biosciences, Inc. CSTL
  • Codexis, Inc. CDXS
  • Fulgent Genetics, Inc. FLGT
  • Guardant Health, Inc. GH
  • Immunocore Holdings plc IMCR
  • Maravai LifeSciences Holdings, Inc. MRVI
  • Mesa Laboratories, Inc. MLAB
  • Myriad Genetics, Inc. MYGN
  • Natera, Inc. NTRA
  • NeoGenomics, Inc. NEO
  • Pacific Biosciences of California, Inc. PACB
  • Quanterix Corporation QTRX
  • Recursion Pharmaceuticals, Inc. RXRX
  • Sage Therapeutics, Inc. SAGE
  • Twist Bioscience Corporation TWST
  • Veracyte, Inc. VCYT
  • Voyager Therapeutics, Inc. VYGR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 5, 2026=◇◇◇
2024June 10, 2025=◇◇◇
2023June 7, 2024=◇◇◇
2022June 9, 2023=◇◇◇
2021June 10, 2022=◇◇◇
2020June 11, 2021=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Adaptive Biotechnologies files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Adaptive Biotechnologies disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Adaptive Biotechnologies sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Adaptive Biotechnologies' disclosed peer group is defensible, who names Adaptive Biotechnologies back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
201 figures on this page: 195 cited to the filing that reported them, 6 calculated from figures it prints.
195 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001193125-26-263844
  2. 0001193125-26-177409
    CEO Pay Ratio · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Outstanding Equity Awards as of December 31, 2025 · and 1 more section
  3. 0001193125-25-140017
  4. 0001193125-25-103752
    Summary Compensation Table
  5. 0000950170-24-071913
  6. 0001193125-24-118168
    Summary Compensation Table
  7. 0000950170-23-027702
  8. 0001193125-23-126845
    Summary Compensation Table
  9. 0001564590-22-023130
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001564590-21-032783
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Adaptive Biotechnologies executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ADPT (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Adaptive Biotechnologies and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Adaptive Biotechnologies discloses

The companies named in ADPT's own disclosed peer group.

Allogene Therapeutics, Inc.Maravai LifeSciences Holdings, Inc.Pacific Biosciences of California, Inc.Quanterix CorporationRecursion Pharmaceuticals, Inc.Twist Bioscience Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy